| Name | Title | Contact Details |
|---|
AmerisourceBergen (NYSE: ABC) is one of the world`s largest pharmaceutical sourcing and distribution services companies, working alongside healthcare providers and pharmaceutical manufacturers to improve access to products and enhance patient care. With services ranging from drug distribution and supply chain management to patient support solutions and pharmaceutical commercialization, AmerisourceBergen enables quality care and innovation in human and animal health. Tens of thousands of pharmacies, physician practices, health systems, veterinary practices, livestock producers and pharmaceutical manufacturers turn to AmerisourceBergen for the expertise they need to drive business performance. With more than $135 billion in annual revenue and 18,000 global associates, AmerisourceBergen is ranked #12 on the Fortune 500 and #1 on the Barron`s 500. The company is headquartered in Valley Forge, Pa., with a network of 140+ offices in 50+ countries.
At Tomorrow Health, we believe you deserve an exceptional experience for care at home. That`s why we`re bringing together personal service and modern technology to get you the products and supplies you need, covered by your health insurance and delivered right to your door.
Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs` technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs` strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy that are currently not being treated. In many pulmonary diseases, including RDS, acute lung injury (ALI), and other respiratory conditions, surfactant is either deficient or may fail to function properly. Our precision-engineered, peptide-containing KL4 surfactant has been designed to mimic the essential function of human pulmonary surfactant and may have the potential to address conditions such as these. We are developing our proprietary delivery technologies to one day enable efficient, targeted upper-respiratory or alveolar delivery of our KL4 surfactant in aerosolized form to allow for a gentler, less invasive delivery approach. These same delivery systems may also potentially be used to deliver a variety of additional aerosolized medicines safely and in a simplified way compared with the current standard of care.
Blooma nourishes the mind, body and spirit of moms-to-be, new mamas and their families through yoga, barre and childbirth education classes.
MMM Healthcare is a San Juan, PR-based company in the Healthcare, Pharmaceuticals, & Biotech sector.